Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 9, 2009, Pages 1161-1166

  Lee, H W ^a,b   Kim, D W ^a,b   Park, J H ^c   Kim, S D ^a   Lim, M S ^a,b   Phapale, P B ^a,b   Kim, E H ^a   Park, S K ^c   Yoon, Young Ran ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c National Masan Hospital   (South Korea)

Author keywords

MDR TB; Pharmaco kinetics; Prothionamide

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; STREPTOMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BODY MASS INDEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; EMACIATION; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PROTHIONAMIDE; REPUBLIC OF KOREA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 70349211935     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance 2002-2007: fourth global report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
2. Bai G H, Park Y K, Choo Y W, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007; 11: 571-576.
3. Park S K, Lee W C, Lee D H, Mitnick C D, Han L, Seung K J. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-368. (Pubitemid 38624874)
4. Ollé-Goig J E, Sandy R. Outcomes of individualized treatment for multidrug-resistant tuberculosis before DOTS-Plus. Int J Tuberc Lung Dis 2005; 9: 765-770. (Pubitemid 41139129)
5. Peloquin C A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183. (Pubitemid 35252827)
6. Jenner P J, Smith S E. Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Lepr Rev 1987; 58: 31-37.
7. Jenner P J, Ellard G A. High performance liquid chromatographic determination of ethionamide and prothionamide in body fluids. J Chromatogr 1981; 225: 245-251.
8. Jenner P J, Ellard G A, Gruer P J K, Aber V R. A comparison of the blood levels and urinary excretion of ethionamide and prothionamide in man. J Antimicrob Chemother 1984; 13: 267-277.
9. Yew W W, Cheung S W, Chau C H, et al. Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy [abstract]. Int J Clin Pharmacol Res 1999; 19: 65-71.
10. Peloquin C A, MacPhee A A, Berning S E. Malabsorption of antimycobacterial medications. N Eng J Med 1993; 329: 1122-1123.
11. Park S K, Yoon Y R, Lee W C, et al. Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis. Tuberc Respir Dis (Korea) 2002; 52: 128-136. (Pubitemid 34534744)
12. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Technical Report Series No. 894. Geneva, Switzerland: WHO, 2000.
13. James W P T, Chunming C, Inuoe S. Appropriate Asian body mass indices? Obes Rev 2002; 3: 139.
14. Bartels H, Bartels R. Simple, rapid and sensitive determination of prothionamide in human serum by high-performance liquid chromatography. Chromatogr B Biomed Sci Appl 1998; 707: 338-341.
15. Wang F, Langley R, Gulcin G, et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med 2007; 204: 73-78. (Pubitemid 46148758)
16. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532. (Pubitemid 23053828)
17. Venkatesan K. Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin Pharmacokinet 1989; 16: 365-386. (Pubitemid 19167716)
18. Handbook of anti-tuberculosis agents. Prothionamide. Tuberculosis (Edinb) 2008; 88: 139-140.
19. Fajardo T T, Guinto R S, Cellona R V, Abalos R M, Dela Cruz E C, Gelber R H. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am J Trop Med Hyg 2006; 74: 457-461.
20. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
21. Rieder H L. Interventions for tuberculosis control and elimination. Paris, France: International Union Against Tuberculosis and Lung Disease, 2002: p 161.
22. Zhu M, Namdar R, Stambaugh J J, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis 2002; 82: 91-96. (Pubitemid 35155424)
23. Handbook of anti-tuberculosis agents. Ethionamide. Tuberculosis (Edinb) 2008; 88: 106-108.
24. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
25. Li J, Burzynski J N, Lee Y A, et al. Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest 2004; 126: 1770-1776. (Pubitemid 39643978)
26. Centers for Disease Control and Prevention. Treatment of tuberculosis: American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 2003; 52: 44.